Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Otsuka Reports Interim Phase 2b/c Data Indicating New Compound May Shorten Tuberculosis
Details : OPC-167832 (quabodepistat) is a potent and orally active dprE1 inhibitor, which is being evaluated in combination with delamanid & bedaquiline for the treatment of pulmonary tuberculosis.
Product Name : OPC-167832
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2024
Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The PAN-TB collaboration is a first-of-its-kind effort to accelerate development of a drug regimen capable of treating all forms of TB, and identifying promising regimens for further development including OPC-167832.
Product Name : OPC-167832
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 17, 2022
Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $17.8 million
Deal Type : Funding
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-TB Combo
Details : The grant will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid and Johnson & Johnson’s bedaquiline, for patients with drug-susceptible pulmonary tuberculosis (DS-TB).
Product Name : OPC-167832
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 08, 2021
Lead Product(s) : OPC-167832,Bedaquiline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $17.8 million
Deal Type : Funding